Journal of Hematology Oncology Pharmacy

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

Featured Articles

Original Article

Time to First Palbociclib Prescription Dispense at Mayo Clinic: Comparing a Health-System Specialty Pharmacy with External Specialty Pharmacies

Case Reports

Complete Pathologic Response to Pembrolizumab in a Patient with Cutaneous Angiosarcoma: Case Report

Case Reports

Isavuconazonium Sulfate Dosing in Pediatric Patients Using Serum Therapeutic Drug Monitoring at a Single Center: A Case Series

Original Article

Evaluating Institutional Safety Standards Related to Continuing Oral Antineoplastic Medication Use During Hospitalization

Practical Issues in Pharmacy Management

Implementation and Evaluation of a Formal Investigational Drug Service at a Community Cancer Center

Original Article

Impact of Pharmacist Telephone Follow-Up on Chemotherapy-Induced Nausea and Vomiting

FDA Oncology Update

Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion

Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer

Pedmark First Drug Approved for Hearing Loss Prevention in Children with Solid Tumors

Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion

Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer

Pemazyre Receives New Indication for FGFR1-Positive Myeloid/Lymphoid Neoplasms

Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease

Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer

Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer

Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer